Multidisciplinary management of adult anaplastic astrocytomas

Seminars in Radiation Oncology

Volumn 11, Issue 2, 2001, Pages 163-169

  Chang, Susan ^a,b   Theodosopoulos, Philip ^a   Sneed, Penny ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTINEOPLASTIC AGENT; CARMUSTINE; CISPLATIN; DIAZIQUONE; LOMUSTINE; PROCARBAZINE; PROTEIN P53; TEMOZOLOMIDE; VINCRISTINE;

ADULT; ANGIOGENESIS; CANCER ADJUVANT THERAPY; CANCER INVASION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; GENE THERAPY; GLIOBLASTOMA; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; MULTIMODALITY CANCER THERAPY; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE; RECURRENT CANCER; REVIEW;

EID: 0035074007     PISSN: 10534296     EISSN: None     Source Type: Journal    
DOI: 10.1053/srao.2001.21428     Document Type: Article

References (41)

1. Procarbazine, lomustine and vincristine (PCV) chemotherapy for anaplastic astrocytoma: A retrospective review of Radiation Therapy Oncology Group Protocols comparing survival with carmustine or PCV adjuvant chemotherapy
2. Cancer Statistics
3. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials
4. Highly anaplastic astrocytoma: A review of 357 patients treated between 1977 and 1989
5. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas
6. Quantitative imaging study of extent of surgical resection and prognosis of malignant astrocytomas
7. Supratentorial gliomas: Surgical considerations and immediate postoperative results. Gross total resection versus partial resection
8. Does extent of surgery influence outcome for astrocytoma with atypical or anaplastic foci (AAF)? A report of S Radiation Therapy Oncology Group trials
9. Supratentorial anaplastic gliomas in adults: The prognostic importance of extent of resection and prior low-grade glioma
10. Functional cortex and subsortical white matter located within gliomas
11. Development and implementation of intraoperative magnetic resonance imaging and its neurosurgical applications
12. Contemporary approaches to the treatment of malignant gliomas with radiation therapy
13. Results of a randomized trial comparing BCNU plus radiotherapy, streptozocin plus radiotherapy, BCNU plus hyperfractionated radiotherapy, and BCNU following misonidazole plus radiotherapy in the postoperative treatment of malignant glioma
14. Misonidazole combined with hyperfractionation in the management of malignant glioma
15. Superfractionation radiation therapy in the treatment of malignant astrocyroma
16. Malignant astrocytoma: Hyperfractionated and standard radiotherapy with chemotherapy in a randomized prospective clinical trial
17. A randomized trial of accelerated hyperfractionated radiation therapy and BCNU for malignant glioma
18. Final report of a Phase I/II trial of hyperfractionated and accelerated hyperfractionated radiation therapy with carmustine for adults with supratentorial malignant gliomas: Radiation Therapy Oncology Group Study 83-02
19. Interstitial brachytherapy procedures for brain tumors
20. Radiosurgery as part of the initial management of patients with malignant gliomas
21. Radiation Therapy Oncology Group (RTOG) survival data on anaplastic astrocytomas of the brain: Does a more aggressive form of treatment adversely impact survival?
22. A randomised comparison of misonidazole sensitized radiotherapy plus BCNU and radiotherapy plus BCNU for treatment of malignant glioma after surgery: Final report of an RTOG study
23. A phase III randomized prospective trial of external beam radiotherapy, mitomycin C, carmustine and 6-mercaptopurine for the treatment of adults with anaplastic glioma of the brain
24. National cancer Institute (Phase II) study of high-grade glioma treated with accelerated hyperfractionated radiation and iododeoxyuridinr: Results in anaplastic astrocytoma
25. Survival improvement in anaplastic astrocytoma, combining external radiation with halogenated pyrimidines: Final report of RTOG 86-12, phase I-II study
26. A phase 3 randomized study of radiotherapy plus procarbazine, CCNU, and vincristine (PCV) with or without BUdR for the treatment of anaplastic astrocytoma: A preliminary, report of RTOG 9404
27. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas
28. Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults
29. Chemotherapy in high-grade glioma: A meta-analysis using individual patient data from randomized clinical trials (RCTS)
30. Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report
31. Medical Research Council (MRC) randomized trial of adjuvant chemotherapy in high grade glioma (HGG)
32. Randomized comparison of diaziquone and carmustine in the treatment of adults with anplastic glioma
33. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse
34. A randomized comparison of intraarterial versus intravenous BCNU, with or without intravenous 5-fluorouracil, for newly diagnosed patients with malignant glioma
35. Adjuvant and Neoadjuvant Treatment for primary brain tumors in adults
36. Complete and partial responses of newly diagnosed malignant astrocytomas following continuous infusion BCNU and cisplatin
37. A phase II trial of continuous infusion chemotherapy, external beam radiotherapy and local boost radiotherapy for malignant gliomas
38. Phase III study comparing 3 cycles of infusional BCNU/cisplatin followed by radiation with radiation and concurrent BCNU for patients with newly diagnosed supratentorial GBM: ECOG 2394-SWOG 4508
39. 6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma
40. Multimodality management of recurrent adult malignant gliomas: Results of a phase II multiagent chemotherapy study and analysis of cytoreductive surgery
41. Outcomes and prognostic factors in recurrent glioma patients enrolled in phase II clinical trials